@microbiologic

Microbial ecologist and entrepreneur with interest in translating scientific discoveries into transformative technologies and therapeutics. Tweets own opinions.

 Cambridge, MA
linkedin.com/pub/matthew-henn/2/35b/424
Joined November 2011
  • Tweets134
  • Following290
  • Followers208
7Media
BREAKING: The first orally administered #microbiota-based therapeutic has been approved by the U.S. FDA. Learn more: bit.ly/3Aye4IO
3
16
11
57
10,669
Matthew Henn retweeted
STAT
@statnews26 Apr 2023
The FDA approved a new drug from Seres Therapeutics that uses bacteria to treat a bowel disorder, making it the second microbiome therapy to hit the market. trib.al/s0Zoted

FDA approves Seres microbiome drug, as field advances

The FDA approved a new drug from Seres Therapeutics that uses bacteria to treat a bowel disorder, making it the second microbiome therapy to hit the market.

statnews.com
3
1
5
4,368
Matthew Henn retweeted
Bruce Booth
@LifeSciVC17 Mar 2022
Biotech Bears: Jumping A Lower Bar Or A Higher One? A few thoughts on what's behind the negative data slump in #biotech. lifescivc.com/2022/03/biotec… $XBI $NBI

Biotech Bears: Jumping A Lower Bar Or A Higher One? - LifeSciVC

Biotech sentiment is super bearish today, as the sector has been crushed over the last year. There’s blood in the water, especially for small and mid-cap players, and everyone’s looking for what...

lifescivc.com
12
31
18
169
We’re deeply saddened by the passing of Nancy Caralla, founder of @cdiffFoundation & an influential patient advocate within the C. diff community. We were honored to work with Nancy & will miss her kind spirit. Seres is dedicated to continuing her legacy.
2
3
2
12
We are excited to announce that data from our Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral #microbiome therapeutic for recurrent #Cdiff infection, was published in the New England Journal of Medicine. Learn more: bwnews.pr/3fCThcy @NEJM
2
12
3
23
Did you miss our presentation at the 40th Annual J.P. Morgan Healthcare Conference this morning? A recording of the webcast is now available. Watch: bit.ly/3tl79QR #JPM22 #JPM2022 #ICYMI
1
6
6
Today, our Chief Scientific Officer & EVP @microbiologic joins the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria to discuss the potential for #microbiome live biotherapeutics (2:30pm ET). Learn more: bit.ly/3d6HlyE #SeresProud #PACCARB @HHSGov
3
5
Our R&D team enjoyed some time reconnecting with each other outdoors in Kendall Square. #SeresProud
2
4
Seres Chief Medical Officer and EVP Lisa von Moltke, MD, FCP discusses our work developing emerging #microbiome therapeutics to treat gastrointestinal conditions with @finding_genius. Listen here: bit.ly/37541fH #SeresProud
4
3
We’re #SeresProud to announce we’ve entered into a strategic collaboration with @NestleNHSc to jointly commercialize SER-109, our investigational oral #microbiome therapeutic for recurrent #Cdiff, in the U.S. & Canada. Read more: bwnews.pr/2UXSAUf
1
5
2
16
#WorldMicrobiomeDay isn’t over yet! Celebrate by testing your knowledge of the human microbiome: worldmicrobiomeday.com/human… #Microbiomes4Life @WMicrobiomeDay
2
4
Matt Henn (@microbiologic) here, and I’m taking over @SeresTX today as we dive into Day 1 of #DDW2021. Be sure to follow along!
1
9
My colleague Lisa von Moltke talks with #Cdiff survivor & @cdiffFoundation Volunteer Health Advocate Coordinator, Kathy Bischoff, about her experience & how microbiome therapy could potentially help #patients. Watch here: #DDW2021 linkedin.com/feed/update/urn…
3
5
#Cdiff survivor Kathy couldn’t have said it better: “If it weren’t for advocating on my own behalf, I would've been one of the 20,000 that does not survive C. diff. Education is key, and there is hope on the horizon.” bit.ly/3oAG0Fd @cdiffFoundation #DDW2021
2
5
Halfway through Day 1 of #DDW2021 and feeling inspired by Dr. Mark Wilcox’s plenary session, “Are We There Yet? Role of Defined Microbial Consortia in Treatment of GI Disease.” Dr. Wilcox shared an in-depth look at #microbiome therapeutics and the Seres platform.
5
13
If you’re at @IDWeek2020, stop by our booth to learn more about our #microbiome therapeutic approach to #cdiff and our ongoing open-label trial! Seres’ team members will be on hand to answer your questions from 1:45-3:45 p.m. ET today at #IDweek2020.
3
4
Matthew Henn retweeted
Joe Walsh
@WalshFreedom12 Jan 2020
Donald Trump and Republican Party bosses have cancelled primaries all over the country. It’s wrong. It’s un-American. Help us make clear to Trump that we won’t tolerate this authoritarian crap here in America.
181
463
63
1,663
Check out our latest paper! Thanks @mSystemsJ for organizing this Early-Career Special Issue! Toward Autonomous Antibiotic Discovery msystems.asm.org/content/4/3…
8
14
Mougous & co: #Pseudomonas aeruginosa secretes conditionally active type VI effectors (#T6SS) that can synergize with other effectors & enable better competition in varied conditions: rdcu.be/HlEH
1
10
4
17
Nice review from @AsherMullard of progress in advancing microbiome programs to the clinic for I/O applications xitter.cf/AsherMullard/status/96…
Asher Mullard@AsherMullard16 Feb 2018
First microbiome+immuno-oncology trial set to start in March, with others close behind. Lots of industry interest, and open questions, via @NatRevDrugDisc rdcu.be/G88A
1
13
13
Load more